You have 0 items in your cart
For several years, GLP-1 receptor agonists have dominated discussion around metabolic research. But another hormone pathway is receiving increasing scientific attention: amylin.
One of the most prominent compounds in this field is cagrilintide.
Cagrilintide is being investigated both independently and in combination with semaglutide, where the combination is known as CagriSema.
So what is cagrilintide, what is amylin, and why has this area become such an important part of next-generation metabolic research?
What Is Cagrilintide?
Cagrilintide is an investigational long-acting amylin analogue developed by Novo Nordisk.
Amylin is a naturally occurring peptide hormone that is produced alongside insulin by pancreatic beta cells.
Rather than primarily targeting the GLP-1 receptor, cagrilintide is designed to reproduce aspects of amylin signalling.
This makes it scientifically distinct from compounds such as semaglutide and from multi-receptor agonists such as retatrutide.
Cagrilintide remains investigational and its clinical development continues.
What Is Amylin?
Amylin is a 37-amino-acid peptide hormone involved in metabolic regulation.
It is released from pancreatic beta cells alongside insulin following food intake.
Researchers have studied amylin’s involvement in several physiological processes, including signalling associated with satiety, gastric emptying and glucagon regulation.
This has made the amylin system an increasingly important research target.
However, naturally occurring human amylin presents challenges for pharmaceutical development, including its tendency to aggregate.
Researchers have therefore developed modified amylin analogues designed to provide properties more suitable for scientific and clinical investigation.
How Does Cagrilintide Work?
Cagrilintide is designed as a long-acting analogue of amylin.
Its mechanism therefore differs from GLP-1 receptor agonists.
This distinction is important because metabolic regulation involves numerous interconnected signalling systems rather than a single pathway.
Researchers are increasingly investigating whether targeting complementary pathways may produce different physiological responses than targeting one pathway alone.
That idea has helped drive interest in amylin-based compounds.
Cagrilintide vs GLP-1
Cagrilintide and GLP-1 receptor agonists shouldn’t simply be considered different versions of the same thing.
They act through different biological systems.
GLP-1-based research primarily examines signalling through the GLP-1 receptor.
Cagrilintide research focuses on the amylin pathway.
The scientific interest becomes particularly interesting when these pathways are studied together.
That leads directly to one of the most closely followed programmes in current metabolic research: CagriSema.
What Is CagriSema?
CagriSema combines two investigational components:
Cagrilintide + semaglutide
Semaglutide targets the GLP-1 receptor, while cagrilintide acts through amylin-related signalling.
The combination therefore allows researchers to investigate two different metabolic pathways simultaneously.
Novo Nordisk has been studying CagriSema within its Phase 3 REDEFINE clinical programme.
Research has included adults with obesity or overweight, both with and without type 2 diabetes.
CagriSema remains investigational.
Why Combine Amylin and GLP-1?
This question reflects a much larger development occurring across metabolic science.
Researchers increasingly aren’t asking only:
“What happens if we target this receptor?”
They’re also asking:
“What happens if complementary biological pathways are targeted together?”
This has produced several different research strategies.
Some compounds activate multiple receptors within a single molecule.
Retatrutide, for example, is designed to activate GIP, GLP-1 and glucagon receptors.
CagriSema takes another approach by combining an amylin analogue with a GLP-1 receptor agonist.
Both approaches illustrate the movement towards multi-pathway metabolic research.
Cagrilintide vs Retatrutide
These compounds are sometimes discussed together, but scientifically they represent substantially different approaches.
Retatrutide is a single investigational molecule with activity at three receptors: GIP, GLP-1 and glucagon.
Cagrilintide is a long-acting amylin analogue.
And CagriSema combines cagrilintide with the GLP-1 receptor agonist semaglutide.
Therefore, comparing them simply as competing versions of the same compound misses an important scientific distinction.
Their mechanisms are different.
This is precisely what makes comparisons between them scientifically interesting.
Why Is Amylin Research Growing?
Amylin itself isn’t a newly discovered hormone.
What has changed is researchers’ ability to develop longer-acting analogues and investigate them alongside other metabolic pathways.
Several amylin-related programmes are now being investigated, including cagrilintide and other emerging compounds.
The broader research landscape is therefore moving beyond a predominantly GLP-1-centred discussion.
Amylin signalling is increasingly becoming part of the conversation surrounding the next generation of metabolic research.
Is Cagrilintide a Peptide?
Cagrilintide is a peptide-based analogue of the naturally occurring peptide hormone amylin.
The distinction between naturally occurring amylin and engineered amylin analogues is important.
Researchers can modify peptide structures to alter characteristics such as stability and duration of activity.
Understanding those differences is important when interpreting scientific literature involving peptide analogues.
Is Cagrilintide Approved?
Cagrilintide remains an investigational compound.
Research findings should not be interpreted as evidence that an investigational compound has been approved for routine medical use.
Clinical development involves multiple phases designed to examine efficacy, safety, tolerability and other outcomes before regulators determine whether a medicine should be authorised.
Amylin Could Be an Important Part of the Next Research Wave
The growing interest in cagrilintide illustrates something bigger than the development of one compound.
Metabolic research is becoming increasingly focused on multiple complementary biological pathways.
GLP-1 remains extremely important, but researchers are now investigating GIP, glucagon, amylin and combinations of these signalling systems.
Cagrilintide provides one of the clearest examples of this shift.
As results from cagrilintide, CagriSema and other amylin programmes continue to emerge, scientists should gain a much clearer understanding of where amylin signalling fits within the rapidly changing metabolic research landscape.
⸻
Research Notice: This article is provided for educational and scientific-information purposes. Cagrilintide and CagriSema are investigational programmes. This content does not constitute medical advice, treatment guidance or dosing information.